药物相关门静脉肝窦血管性疾病

摘要/Abstract

摘要： 门静脉肝窦血管性疾病(porto-sinusoidal vascular disorder, PSVD)作为对非肝硬化门静脉高压(non-cirrhotic portal hypertension, NCPH)的补充,可被多种药物诱发。药物诱发的PSVD多进展缓慢,停药后可自行恢复,部分进行性进展,直至出现门静脉高压。一旦进展至临床显著性门静脉高压(clinically significant portal hypertension, CSPH),则不良事件明显增多、预后不佳。对于已经进展至CSPH阶段的患者,需参照NCPH进行临床管理。

张晓丰, 陈金军. 药物相关门静脉肝窦血管性疾病[J]. 肝脏, 2024, 29(12): 1454-1456.

/ 推荐

参考文献

[1] De Gottardi A, Sempoux C, Berzigotti A. Porto-sinusoidal vascular disorder[J]. J Hepatol, 2022,77(4):1124-1135.
[2] De Gottardi A, Rautou PE, Schouten J, et al; VALDIG group. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet gstroenterol Hepatol,2019, 4(5):399-411.
[3] Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy[J]. Am J gastroenterol,2009, 104(7):1707-1714.
[4] Toksvang LN, Schmidt MS, Arup S, et al. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review[J]. PLoS One,2019,14(5):e0212157.
[5] Ghabril M, Vuppalanchi R. Drug-induced nodular regenerative hyperplasia[J]. Semin Liver Dis,2014,34(2):240-245.
[6] Lee H, Rehman AU, Fiel MI. Idiopathic Noncirrhotic Portal Hypertension: An Appraisal[J]. J Pathol Transl Med,2016,50(1):17-25.
[7] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Trastuzumab. 2024 Jan 30.
[8] Puente A, Fortea JI, Del Pozo C, et al. Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It[J]. Cells,2019,8(12):1506.
[9] Vigano L, De Rosa G, Toso C, et al. Reversibility of chemotherapy-related liver injury[J]. J Hepatol,2017,67(1):84-91.
[10] Wicherts DA, de Haas RJ, Sebagh M, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases[J]. Ann Surg Oncol,2011,18(3):659-669.
[11] Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis[J]. Histopathology,2010, ,56(4):430-439.
[12] Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury[J]. J Clin Oncol,2010,28(15):2549-2555.
[13] Overman MJ, Ferrarotto R, Raghav K, et al. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia[J]. J Natl Cancer Inst,2018,110(8):888-894.
[14] Simsek M, Deben DS, Horjus CS, et al. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies[J]. Aliment Pharmacol Ther,2019,50(1):54-65.
[15] Toksvang LN, Schmidt MS, Arup S, et al. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review[J]. PLoS One,2019 ,14(5):e0212157.
[16] Simsek M, Meijer B, Ramsoekh D, et al; Dutch Initiative on Crohn and Colitis (ICC). Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients[J]. Clin Gastroenterol Hepatol,2019,17(3):568-570.
[17] Logan S, Rodger A, Maynard-Smith L, et al. Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study[J]. World J Hepatol,2016,8(36):1623-1628.
[18] Schouten JN, Van der Ende ME, Koëter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension[J]. Aliment Pharmacol Ther, 2012,36(9):875-885.
[19] Cotte L, Bénet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study[J]. J Hepatol, 2011,54(3):489-496.
[20] Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome[J]. Antivir Ther,2008,13(1):103-107.
[21] Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients[J]. AIDS,2009,23(12):1511-1518.
[22] Kim HP, Navarro V, Zacks S, et al; Drug-Induced Liver Injury Network Investigators. The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease[J]. Clin Gastroenterol Hepatol,2021,19(10):2199-2201.
[23] Elkrief L, Lazareth M, Chevret S, et al; ANRS CO12 CirVir Group. Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension[J]. Hepatology, 2021,74(1):364-378.
[24] Ferreira-Silva J, Gaspar R, Liberal R, et al. Splenic-hepatic elastography index is useful in differentiating between porto-sinusoidal vascular disease and cirrhosis in patients with portal hypertension[J]. Dig Liver Dis,2023,55(1):75-80.
[25] Moga L, Paradis V, Ferreira-Silva J, et al; ERN RARE-LIVER; a study of VALDIG, an EASL consortium. Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder[J]. Hepatology,2024.
[26] Maruyama H, Okugawa H, Kobayashi S, et al. Non-invasive portography: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis[J]. Br J Radiol,2012,85(1013):587-595.
[27] Seijo S, Reverter E, Miquel R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension[J]. Dig Liver Dis,2012, 44(10):855-860.
[28] Hu Y, Duan S, Zhang Y, et al. Feasibility and safety of ultrasound-guided percutaneous transhepatic measurement of portal venous pressure[J]. PLoS One,2024,19(7):e0305725.
[29] Wang J, Zhang L, Cheng SM, et al. The evaluation of portal hypertension in cirrhotic patients with spectral computed tomography[J]. Acta Radiol, 2023,64(3):918-925.
[30] Olivas P, Soler-Perromat A, Tellez L, et al. Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient[J]. JHEP Rep,2024,6(10):101170.
[31] Kim HP, Navarro V, Zacks S, et al; Drug-Induced Liver Injury Network Investigators. The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease[J]. Clin Gastroenterol Hepatol,2021 ,19(10):2199-2201.
[32] Meijer B, Simsek M, Blokzijl H, et al. Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units[J]. United European Gastroenterol J,2017,5(5):658-667.